Table 1 Patient demographics and baseline characteristics
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Characteristic | Patients (N = 49), no. (%) |
|---|---|
Median age (range), years | 53 (26–73) |
Sex | |
Female | 20 (41%) |
Male | 29 (59%) |
Diagnosis at enrollment | |
Glioblastoma | 48 (98%) |
Gliosarcoma | 1 (2%) |
Karnofsky Performance Score | |
100 | 10 (20%) |
90 | 28 (57%) |
80 | 6 (12%) |
70 | 5 (10%) |
Recurrences before treatment | |
1 | 39 (80%) |
2 | 10 (20%) |
Baseline tumor size | |
Median maximum diameter (range), mm | 28.5 (11.0–48.2) |
Median tumor area (range), mm2 | 597.2 (110.0–1599.8) |
IDH1 R132 status | |
Mutant | 4 (8%) |
Wild type | 44 (90%) |
Unknown | 1 (2%) |
MGMT gene promoter methylation status | |
Methylated | 14 (29%) |
Unmethylated | 28 (57%) |
Unknown | 7 (14%) |
Prior therapies | |
Surgical resection | 44 (90%) |
Radiotherapy | 49 (100%) |
Temozolomide | 49 (100%) |
Bevacizumab | 6 (12%) |
Tumor treating fields | 5 (10%) |
Baseline dexamethasone use ≥1.5 mg per day | |
Yes | 9 (18%) |
No | 40 (82%) |
